Literature DB >> 16516603

Role of angiotensin receptor blockers in the prevention and treatment of arrhythmias.

Shaila Garg1, Jagat Narula, Claudio Marelli, David Cesario.   

Abstract

The renin-angiotensin system is a key regulatory system that is activated in many forms of cardiovascular disease. It is well established that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are important therapeutic agents in the treatment of hypertension, myocardial infarction, and congestive heart failure. More recent research has suggested that renin-angiotensin system activation may also play a critical role in the genesis of atrial and ventricular arrhythmias. The possible role of renin-angiotensin system activation in arrhythmogenesis suggests that ACE inhibitors and ARBs may be important therapeutic agents in the prevention and treatment of arrhythmias. This review summarizes the current evidence for the use of ARBs in the treatment of atrial and ventricular arrhythmias.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16516603     DOI: 10.1016/j.amjcard.2005.10.028

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

1.  Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat.

Authors:  Marek Matus; Dana Kucerova; Peter Kruzliak; Adriana Adameova; Gabriel Doka; Katarina Turcekova; Jana Kmecova; Jan Kyselovic; Peter Krenek; Uwe Kirchhefer; Frank U Mueller; Peter Boknik; Jan Klimas
Journal:  Mol Cell Biochem       Date:  2015-02-08       Impact factor: 3.396

Review 2.  Modulation of the QT interval duration in hypertension with antihypertensive treatment.

Authors:  Jan Klimas; Peter Kruzliak; Simon W Rabkin
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

3.  Angiotensin receptor type 1 single nucleotide polymorphism 1166A/C is associated with malignant arrhythmias and altered circulating miR-155 levels in patients with chronic heart failure.

Authors:  Raul R Blanco; Harland Austin; Richard N Vest; Ravinder Valadri; Wei Li; Bernard Lassegue; Qing Song; Barry London; Samuel C Dudley; Heather L Bloom; Charles D Searles; A Maziar Zafari
Journal:  J Card Fail       Date:  2012-08-09       Impact factor: 5.712

4.  E-NTPDase1/CD39 modulates renin release from heart mast cells during ischemia/reperfusion: a novel cardioprotective role.

Authors:  Silvia Aldi; Alice Marino; Kengo Tomita; Federico Corti; Ranjini Anand; Kim E Olson; Aaron J Marcus; Roberto Levi
Journal:  FASEB J       Date:  2014-10-15       Impact factor: 5.191

5.  Angiotensin II induces afterdepolarizations via reactive oxygen species and calmodulin kinase II signaling.

Authors:  Zhenghang Zhao; Nadezhda Fefelova; Mayilvahanan Shanmugam; Peter Bishara; Gopal J Babu; Lai-Hua Xie
Journal:  J Mol Cell Cardiol       Date:  2010-11-06       Impact factor: 5.000

Review 6.  Targeting cardiac mast cells: pharmacological modulation of the local renin-angiotensin system.

Authors:  Alicia C Reid; Jacqueline A Brazin; Christopher Morrey; Randi B Silver; Roberto Levi
Journal:  Curr Pharm Des       Date:  2011-11       Impact factor: 3.116

7.  Cardiac oxidative stress and dysfunction by fine concentrated ambient particles (CAPs) are mediated by angiotensin-II.

Authors:  Elisa Ghelfi; Gregory A Wellenius; Joy Lawrence; Emil Millet; Beatriz Gonzalez-Flecha
Journal:  Inhal Toxicol       Date:  2010-09       Impact factor: 2.724

8.  PKC activation and PIP(2) depletion underlie biphasic regulation of IKs by Gq-coupled receptors.

Authors:  Alessandra Matavel; Coeli M B Lopes
Journal:  J Mol Cell Cardiol       Date:  2009-02-20       Impact factor: 5.000

Review 9.  The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias.

Authors:  Shahriar Iravanian; Samuel C Dudley
Journal:  Heart Rhythm       Date:  2008-03-04       Impact factor: 6.343

10.  Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization.

Authors:  Thomas H Langenickel; Pierre Jordaan; Jesika Petruck; Kiran Kode; Parasar Pal; Soniya Vaidya; Priya Chandra; Iris Rajman
Journal:  Eur J Clin Pharmacol       Date:  2016-04-16       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.